Do analysts prefer MOR or SMMT?

Summit Therapeutics has a consensus price target of $26.15, indicating a potential upside of 91.47%. Given Summit Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Summit Therapeutics is more favorable than MorphoSys. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score MorphoSys 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Summit Therapeutics 2 Sell rating(s) 6 Hold rating(s) 7 Buy rating(s) 1 Strong Buy rating(s) 2.44

Do analysts recommend MOR or RDY?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score MorphoSys 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Dr. Reddy's Laboratories 1 Sell rating(s) 2 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.67

Do analysts recommend MOR or CYTK?

Cytokinetics has a consensus target price of $99.90, indicating a potential upside of 23.73%. Given Cytokinetics' stronger consensus rating and higher possible upside, analysts clearly believe Cytokinetics is more favorable than MorphoSys. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score MorphoSys 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Cytokinetics 1 Sell rating(s) 2 Hold rating(s) 17 Buy rating(s) 2 Strong Buy rating(s) 2.91

Which has preferable valuation and earnings, MOR or CYTK?

MorphoSys has higher revenue and earnings than Cytokinetics. Cytokinetics is trading at a lower price-to-earnings ratio than MorphoSys, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio MorphoSys $238.28M 11.99 -$205.35M -$3.48 N/A Cytokinetics $105.82M 94.95 -$784.96M -$6.84 N/A

Is MOR or CYTK more profitable?

MorphoSys has a net margin of -226.79% compared to Cytokinetics' net margin of -784.02%. Cytokinetics' return on equity of 0.00% beat MorphoSys' return on equity. Company Net Margins Return on Equity Return on Assets MorphoSys -226.79% -694.31% -22.55% Cytokinetics -784.02% N/A -52.86%

Do analysts recommend MOR or KRYS?

Krystal Biotech has a consensus price target of $360.67, indicating a potential upside of 7.60%. Given Krystal Biotech's stronger consensus rating and higher possible upside, analysts plainly believe Krystal Biotech is more favorable than MorphoSys. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score MorphoSys 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Krystal Biotech 0 Sell rating(s) 2 Hold rating(s) 10 Buy rating(s) 0 Strong Buy rating(s) 2.83

Which has better earnings & valuation, MOR or KRYS?

Krystal Biotech has higher revenue and earnings than MorphoSys. MorphoSys is trading at a lower price-to-earnings ratio than Krystal Biotech, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio MorphoSys $238.28M 11.99 -$205.35M -$3.48 N/A Krystal Biotech $389.13M 25.39 $204.83M $7.48 44.81

Is MOR or KRYS more profitable?

Krystal Biotech has a net margin of 53.92% compared to MorphoSys' net margin of -226.79%. Krystal Biotech's return on equity of 19.25% beat MorphoSys' return on equity. Company Net Margins Return on Equity Return on Assets MorphoSys -226.79% -694.31% -22.55% Krystal Biotech 53.92% 19.25% 17.62%

MorphoSys (MOR) Competitors

$18.96 0.00 (0.00%)

As of 07/23/2026

Compare

MOR vs. SMMT, ARWR, RDY, CYTK, and KRYS

Should you buy MorphoSys stock or one of its competitors? MarketBeat compares MorphoSys with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with MorphoSys include Summit Therapeutics (SMMT), Arrowhead Pharmaceuticals (ARWR), Dr. Reddy's Laboratories (RDY), Cytokinetics (CYTK), and Krystal Biotech (KRYS). These companies are all part of the "pharmaceutical products" industry.

How does MorphoSys compare to Summit Therapeutics?

MorphoSys (NASDAQ:MOR) and Summit Therapeutics (NASDAQ:SMMT) are both medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their media sentiment, analyst recommendations, earnings, dividends, profitability, institutional ownership, risk and valuation.

Summit Therapeutics has a consensus price target of $26.15, indicating a potential upside of 91.47%. Given Summit Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Summit Therapeutics is more favorable than MorphoSys.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
MorphoSys	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
Summit Therapeutics	2 Sell rating(s)	6 Hold rating(s)	7 Buy rating(s)	1 Strong Buy rating(s)	2.44

MorphoSys has higher revenue and earnings than Summit Therapeutics. Summit Therapeutics is trading at a lower price-to-earnings ratio than MorphoSys, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
MorphoSys	$238.28M	11.99	-$205.35M	-$3.48	N/A
Summit Therapeutics	N/A	N/A	-$1.08B	-$1.60	N/A

18.4% of MorphoSys shares are held by institutional investors. Comparatively, 4.6% of Summit Therapeutics shares are held by institutional investors. 0.1% of MorphoSys shares are held by company insiders. Comparatively, 83.5% of Summit Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Summit Therapeutics has a net margin of 0.00% compared to MorphoSys' net margin of -226.79%. Summit Therapeutics' return on equity of -183.84% beat MorphoSys' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
MorphoSys	-226.79%	-694.31%	-22.55%
Summit Therapeutics	N/A	-183.84%	-154.65%

In the previous week, Summit Therapeutics had 20 more articles in the media than MorphoSys. MarketBeat recorded 20 mentions for Summit Therapeutics and 0 mentions for MorphoSys. Summit Therapeutics' average media sentiment score of 0.20 beat MorphoSys' score of 0.00 indicating that Summit Therapeutics is being referred to more favorably in the news media.

Company	Overall Sentiment
MorphoSys	Neutral
Summit Therapeutics	Neutral

MorphoSys has a beta of 1.2, indicating that its stock price is 20% more volatile than the broader market. Comparatively, Summit Therapeutics has a beta of -1.26, indicating that its stock price is 226% less volatile than the broader market.

Summary

Summit Therapeutics beats MorphoSys on 10 of the 16 factors compared between the two stocks.

How does MorphoSys compare to Arrowhead Pharmaceuticals?

Arrowhead Pharmaceuticals (NASDAQ:ARWR) and MorphoSys (NASDAQ:MOR) are both medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their analyst recommendations, dividends, valuation, institutional ownership, earnings, media sentiment, profitability and risk.

Arrowhead Pharmaceuticals has a net margin of -48.38% compared to MorphoSys' net margin of -226.79%. Arrowhead Pharmaceuticals' return on equity of -55.09% beat MorphoSys' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Arrowhead Pharmaceuticals	-48.38%	-55.09%	-18.13%
MorphoSys	-226.79%	-694.31%	-22.55%

In the previous week, Arrowhead Pharmaceuticals had 40 more articles in the media than MorphoSys. MarketBeat recorded 40 mentions for Arrowhead Pharmaceuticals and 0 mentions for MorphoSys. Arrowhead Pharmaceuticals' average media sentiment score of 0.96 beat MorphoSys' score of 0.00 indicating that Arrowhead Pharmaceuticals is being referred to more favorably in the media.

Company	Overall Sentiment
Arrowhead Pharmaceuticals	Positive
MorphoSys	Neutral

Arrowhead Pharmaceuticals presently has a consensus target price of $93.83, indicating a potential upside of 9.62%. Given Arrowhead Pharmaceuticals' stronger consensus rating and higher probable upside, equities research analysts clearly believe Arrowhead Pharmaceuticals is more favorable than MorphoSys.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Arrowhead Pharmaceuticals	1 Sell rating(s)	3 Hold rating(s)	9 Buy rating(s)	1 Strong Buy rating(s)	2.71
MorphoSys	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

Arrowhead Pharmaceuticals has a beta of 1.26, indicating that its stock price is 26% more volatile than the broader market. Comparatively, MorphoSys has a beta of 1.2, indicating that its stock price is 20% more volatile than the broader market.

Arrowhead Pharmaceuticals has higher revenue and earnings than MorphoSys. Arrowhead Pharmaceuticals is trading at a lower price-to-earnings ratio than MorphoSys, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Arrowhead Pharmaceuticals	$829.45M	14.54	-$1.63M	-$2.15	N/A
MorphoSys	$238.28M	11.99	-$205.35M	-$3.48	N/A

62.6% of Arrowhead Pharmaceuticals shares are held by institutional investors. Comparatively, 18.4% of MorphoSys shares are held by institutional investors. 3.6% of Arrowhead Pharmaceuticals shares are held by insiders. Comparatively, 0.1% of MorphoSys shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Summary

Arrowhead Pharmaceuticals beats MorphoSys on 16 of the 17 factors compared between the two stocks.

How does MorphoSys compare to Dr. Reddy's Laboratories?

MorphoSys (NASDAQ:MOR) and Dr. Reddy's Laboratories (NYSE:RDY) are both mid-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their valuation, risk, profitability, institutional ownership, media sentiment, earnings, dividends and analyst recommendations.

Dr. Reddy's Laboratories has higher revenue and earnings than MorphoSys. MorphoSys is trading at a lower price-to-earnings ratio than Dr. Reddy's Laboratories, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
MorphoSys	$238.28M	11.99	-$205.35M	-$3.48	N/A
Dr. Reddy's Laboratories	$3.58B	2.75	$456M	$0.58	20.30

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
MorphoSys	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
Dr. Reddy's Laboratories	1 Sell rating(s)	2 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.67

18.4% of MorphoSys shares are owned by institutional investors. Comparatively, 3.9% of Dr. Reddy's Laboratories shares are owned by institutional investors. 0.1% of MorphoSys shares are owned by company insiders. Comparatively, 2.0% of Dr. Reddy's Laboratories shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

MorphoSys has a beta of 1.2, suggesting that its stock price is 20% more volatile than the broader market. Comparatively, Dr. Reddy's Laboratories has a beta of 0.25, suggesting that its stock price is 75% less volatile than the broader market.

In the previous week, Dr. Reddy's Laboratories had 14 more articles in the media than MorphoSys. MarketBeat recorded 14 mentions for Dr. Reddy's Laboratories and 0 mentions for MorphoSys. MorphoSys' average media sentiment score of 0.00 beat Dr. Reddy's Laboratories' score of -0.23 indicating that MorphoSys is being referred to more favorably in the media.

Company	Overall Sentiment
MorphoSys	Neutral
Dr. Reddy's Laboratories	Neutral

Dr. Reddy's Laboratories has a net margin of 10.15% compared to MorphoSys' net margin of -226.79%. Dr. Reddy's Laboratories' return on equity of 9.49% beat MorphoSys' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
MorphoSys	-226.79%	-694.31%	-22.55%
Dr. Reddy's Laboratories	10.15%	9.49%	6.32%

Summary

Dr. Reddy's Laboratories beats MorphoSys on 10 of the 14 factors compared between the two stocks.

How does MorphoSys compare to Cytokinetics?

MorphoSys (NASDAQ:MOR) and Cytokinetics (NASDAQ:CYTK) are both medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their risk, media sentiment, dividends, valuation, profitability, institutional ownership, earnings and analyst recommendations.

18.4% of MorphoSys shares are owned by institutional investors. 0.1% of MorphoSys shares are owned by insiders. Comparatively, 2.6% of Cytokinetics shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

In the previous week, Cytokinetics had 10 more articles in the media than MorphoSys. MarketBeat recorded 10 mentions for Cytokinetics and 0 mentions for MorphoSys. Cytokinetics' average media sentiment score of 1.17 beat MorphoSys' score of 0.00 indicating that Cytokinetics is being referred to more favorably in the news media.

Company	Overall Sentiment
MorphoSys	Neutral
Cytokinetics	Positive

MorphoSys has a net margin of -226.79% compared to Cytokinetics' net margin of -784.02%. Cytokinetics' return on equity of 0.00% beat MorphoSys' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
MorphoSys	-226.79%	-694.31%	-22.55%
Cytokinetics	-784.02%	N/A	-52.86%

Cytokinetics has a consensus target price of $99.90, indicating a potential upside of 23.73%. Given Cytokinetics' stronger consensus rating and higher possible upside, analysts clearly believe Cytokinetics is more favorable than MorphoSys.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
MorphoSys	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
Cytokinetics	1 Sell rating(s)	2 Hold rating(s)	17 Buy rating(s)	2 Strong Buy rating(s)	2.91

MorphoSys has a beta of 1.2, meaning that its share price is 20% more volatile than the broader market. Comparatively, Cytokinetics has a beta of 0.42, meaning that its share price is 58% less volatile than the broader market.

MorphoSys has higher revenue and earnings than Cytokinetics. Cytokinetics is trading at a lower price-to-earnings ratio than MorphoSys, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
MorphoSys	$238.28M	11.99	-$205.35M	-$3.48	N/A
Cytokinetics	$105.82M	94.95	-$784.96M	-$6.84	N/A

Summary

Cytokinetics beats MorphoSys on 9 of the 17 factors compared between the two stocks.

How does MorphoSys compare to Krystal Biotech?

MorphoSys (NASDAQ:MOR) and Krystal Biotech (NASDAQ:KRYS) are both mid-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their dividends, risk, profitability, institutional ownership, media sentiment, valuation, earnings and analyst recommendations.

MorphoSys has a beta of 1.2, meaning that its share price is 20% more volatile than the broader market. Comparatively, Krystal Biotech has a beta of 0.5, meaning that its share price is 50% less volatile than the broader market.

18.4% of MorphoSys shares are owned by institutional investors. Comparatively, 86.3% of Krystal Biotech shares are owned by institutional investors. 0.1% of MorphoSys shares are owned by company insiders. Comparatively, 13.1% of Krystal Biotech shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

In the previous week, Krystal Biotech had 11 more articles in the media than MorphoSys. MarketBeat recorded 11 mentions for Krystal Biotech and 0 mentions for MorphoSys. Krystal Biotech's average media sentiment score of 1.52 beat MorphoSys' score of 0.00 indicating that Krystal Biotech is being referred to more favorably in the news media.

Company	Overall Sentiment
MorphoSys	Neutral
Krystal Biotech	Very Positive

Krystal Biotech has a consensus price target of $360.67, indicating a potential upside of 7.60%. Given Krystal Biotech's stronger consensus rating and higher possible upside, analysts plainly believe Krystal Biotech is more favorable than MorphoSys.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
MorphoSys	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
Krystal Biotech	0 Sell rating(s)	2 Hold rating(s)	10 Buy rating(s)	0 Strong Buy rating(s)	2.83

Krystal Biotech has a net margin of 53.92% compared to MorphoSys' net margin of -226.79%. Krystal Biotech's return on equity of 19.25% beat MorphoSys' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
MorphoSys	-226.79%	-694.31%	-22.55%
Krystal Biotech	53.92%	19.25%	17.62%

Krystal Biotech has higher revenue and earnings than MorphoSys. MorphoSys is trading at a lower price-to-earnings ratio than Krystal Biotech, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
MorphoSys	$238.28M	11.99	-$205.35M	-$3.48	N/A
Krystal Biotech	$389.13M	25.39	$204.83M	$7.48	44.81

Summary

Krystal Biotech beats MorphoSys on 15 of the 16 factors compared between the two stocks.

Get MorphoSys News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding MOR and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

MOR vs. The Competition

Export

Metric	MorphoSys	Pharmaceutical Industry	Medical Sector	NASDAQ Exchange
Market Cap	$2.86B	$966.40M	$6.88B	$12.26B
Dividend Yield	N/A	4.84%	2.67%	9.79%
P/E Ratio	-5.45	1.53	27.00	23.71
Price / Sales	11.99	109.17	492.77	76.09
Price / Cash	N/A	20.06	50.54	59.64
Price / Book	54.17	8.48	10.28	6.07
Net Income	-$205.35M	-$3.23M	$3.60B	$331.84M
7 Day Performance	N/A	-2.80%	-1.25%	-1.53%
1 Month Performance	N/A	-4.40%	-0.35%	-2.46%
1 Year Performance	N/A	28.83%	18.41%	13.66%

MorphoSys Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
MOR MorphoSys	N/A	$18.96 flat	N/A	N/A	$2.86B	$238.28M	N/A	730
SMMT Summit Therapeutics	3.52 of 5 stars	$14.74 +0.8%	$26.97 +83.0%	-50.5%	$11.36B	N/A	N/A	110	Trending News Earnings Report Analyst Forecast Options Volume
ARWR Arrowhead Pharmaceuticals	1.9116 of 5 stars	$88.70 +19.0%	$90.83 +2.4%	+426.4%	$10.50B	$829.45M	N/A	400	News Coverage Analyst Forecast High Trading Volume
RDY Dr. Reddy's Laboratories	2.0403 of 5 stars	$11.37 -9.5%	N/A	-19.9%	$10.48B	$3.58B	19.60	27,527	News Coverage Earnings Report Analyst Downgrade
CYTK Cytokinetics	3.5123 of 5 stars	$82.19 +1.3%	$99.90 +21.5%	+116.4%	$10.09B	$88.04M	N/A	250	News Coverage Positive News

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:MOR) was last updated on 7/25/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

MorphoSys (MOR) Competitors

MOR vs. SMMT, ARWR, RDY, CYTK, and KRYS

How does MorphoSys compare to Summit Therapeutics?

Summary

How does MorphoSys compare to Arrowhead Pharmaceuticals?

Summary

How does MorphoSys compare to Dr. Reddy's Laboratories?

Summary

How does MorphoSys compare to Cytokinetics?

Summary

How does MorphoSys compare to Krystal Biotech?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

MOR vs. The Competition

MorphoSys Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

MorphoSys (MOR) Competitors

MOR vs. SMMT, ARWR, RDY, CYTK, and KRYS

How does MorphoSys compare to Summit Therapeutics?

Do analysts prefer MOR or SMMT?

Which has better earnings and valuation, MOR or SMMT?

Do insiders and institutionals believe in MOR or SMMT?

Is MOR or SMMT more profitable?

Does the media refer more to MOR or SMMT?

Which has more risk & volatility, MOR or SMMT?

Summary

How does MorphoSys compare to Arrowhead Pharmaceuticals?

Is ARWR or MOR more profitable?

Does the media prefer ARWR or MOR?

Do analysts recommend ARWR or MOR?

Which has more volatility and risk, ARWR or MOR?

Which has preferable earnings and valuation, ARWR or MOR?

Do institutionals & insiders believe in ARWR or MOR?

Summary

How does MorphoSys compare to Dr. Reddy's Laboratories?

Which has higher earnings and valuation, MOR or RDY?

Do analysts recommend MOR or RDY?

Do institutionals and insiders believe in MOR or RDY?

Which has more volatility & risk, MOR or RDY?

Does the media refer more to MOR or RDY?

Is MOR or RDY more profitable?

Summary

How does MorphoSys compare to Cytokinetics?

Do institutionals & insiders believe in MOR or CYTK?

Does the media refer more to MOR or CYTK?

Is MOR or CYTK more profitable?

Do analysts recommend MOR or CYTK?

Which has more volatility and risk, MOR or CYTK?

Which has preferable valuation and earnings, MOR or CYTK?

Summary

How does MorphoSys compare to Krystal Biotech?

Which has more risk & volatility, MOR or KRYS?

Do insiders & institutionals believe in MOR or KRYS?

Does the media refer more to MOR or KRYS?

Do analysts recommend MOR or KRYS?

Is MOR or KRYS more profitable?

Which has better earnings & valuation, MOR or KRYS?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

MOR vs. The Competition

MorphoSys Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools